Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab Plus Axitinib Vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial.

Mehmet A. Bilen,Brian Rini,Martin H. Voss,James Larkin,John B. A. G. Haanen,Laurence Albiges,Lance C. Pagliaro,Eric G. Voog,Elaine T. Lam,Nikolay Kislov,Bradley A. McGregor,Aly-Khan A. Lalani,Bo Huang,Alessandra di Pietro,Stan Krulewicz,Paul B. Robbins,Toni K. Choueiri

pubmed（2023）

引用 10|浏览17

暂无评分

摘要

Supplementary Data from Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

查看译文

关键词

Renal Cell Carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要